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The 2005 National Institute of Health (NIH) Consensus Conference outlined histopathological diagnostic
criteria for the major organ systems affected by both acute and chronic graft-versus-host disease (GVHD). The
2014 Consensus Conference led to this updated document with new information from histopathological
studies of GVHD in the gut, liver, skin, and oral mucosa and an expanded discussion of GVHD in the lungs and
kidneys. The recommendations for ﬁnal histological diagnostic categories have been simpliﬁed from 4 cat-
egories to 3: no GVHD, possible GVHD, and likely GVHD, based on better reproducibility achieved by
combining the previous categories of “consistent with GVHD” and “deﬁnite GVHD” into the single category of
“likely GVHD.” Issues remain in the histopathological characterization of GVHD, particularly with respect to
the threshold of histological changes required for diagnostic certainty. Guidance is provided for the incor-
poration of biopsy information into prospective clinical studies of GVHD, particularly with respect to
biomarker validation.
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Histopathology has played a major role in understanding
the pathophysiology and aiding in the diagnosis and man-
agement of graft-versus-host disease (GVHD). Historically,
the clinicopathologic classiﬁcations of both acute [1] and
chronic GVHD were derived from a cohort of patients in the
late 1970s [2]. Many of these early cases were untreated orMarrow Transplantation.
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available at the time. Descriptions and illustrations of fully
developed histological lesions of acute and chronic GVHD
can be reviewed in several texts [1,3-8]. Changes in trans-
plantation modalities, eg, reduced-intensity conditioning,
hematopoietic stem cell source, and post-transplantation
immunosuppression therapies, affect the onset of GVHD
and the frequency of chronic GVHD [9].
Since the initial publication of the Pathology Working
Group Report from the National Institutes of Health (NIH)
Consensus Development Project on chronic GVHD [10], many
practical issues in the surgical pathology of GVHD remain
unresolved or not addressed in standard texts. It is often
neither possible nor meaningful to distinguish persistent,
recurrent, or late acute GVHD from chronic GVHD by his-
tology. Furthermore, uniform minimal histological diag-
nostic criteria for GVHD have not been established and
remain a subject of study. Some advances in histological
analysis have been made. Recent studies quantifying the
macrophage content in skin biopsies [11] or Paneth cell loss
in the intestinal crypts [12] suggest that steroid responsive-
ness can be predicted. A growing body of evidence indicates
that, in addition to damage to targeted epithelia, changes to
the microvascular endothelium play a role in the pathogen-
esis of GVHD [13-17]. It is controversial whether the endo-
thelium is a target of GVHD or is damaged secondarily from
cytotoxic T lymphocytes or inﬂammatory cytokines,
including tumor necrosis factor, interferon gamma, and nitric
oxide, as well as some of the immunosuppressive agents.
Additional studies related to the role of the endothelium are
discussed in the skin and renal sections below.
To facilitate clinical trials of chronic GVHD, uniformly
applied and interpreted criteria for histopathological di-
agnoses are necessary. These criteria should be shown to be
reproducible by multi-institutional studies and correlated
with clinical information. Ideally, chronic GVHD trials should
incorporate protocol-directed biopsies from scheduled cal-
endar or event-driven collection procedures to allow corol-
lary histopathological studies. This issue is further addressed
at the end of this document.PURPOSE OF THIS DOCUMENT
The purpose of this report is to provide an update for
pathologists and clinicians on the interpretation of biopsies
and use of this information in the management of hemato-
poietic cell transplantation (HCT) patients, with a focus on
changes since our ﬁrst publication [10]. This update includes
new information relevant to interpretation of histopatholo-
gy, together with expanded discussions of microvascular,
pulmonary, and renal pathology in HCT patients. General
guidance on the incorporation of biopsy pathology into
clinical studies is also provided. The recommendations of the
Working Group represent a consensus opinion supple-
mented by evaluation of available peer-reviewed literature.SUMMARY OF CHANGES AND UPDATES
The following list highlights the changes and new infor-
mation presented in this document:
 The discussion has been updated to include speciﬁc
biologic studies based on histology that shed light on
the pathophysiology of chronic GVHD.
 Table 1 has been updated with reﬁnements to the his-
tological criteria of GVHD in each organ. To improve interobserver reproducibility, recommen-
dation for ﬁnal histological diagnosis has been simpli-
ﬁed to 3 categories: “Not GVHD,” “Possible GVHD,” and
“Likely GVHD” (Table 2).
 A single liver biopsy obtained in the midst of
immunosuppression can assess the severity of duct
injury in GVHD but not its trajectory.
 The highest diagnostic yield results from concurrent
sampling of the upper and lower gastrointestinal (GI)
tract. There is no consensus on a limited biopsy strategy
that can be used in preference to wider sampling.
 Histological changes in late-onset colitis after cord
blood transplantation, not associated with an estab-
lished infection (ie, “cord colitis syndrome”), are not
histologically distinct from colonic GVHD.
 Changes of mycophenolate mofetil (MMF)-related gut
injury occur in both the upper and lower GI tract.
 Intestinal Paneth cells are lost as a late occurrence in
severe GI GVHD, and loss of these cells portends a poor
outcome.
 Criteria for assessing the regression of dermal sclerosis
after autologous transplantation for scleroderma have
been deﬁned. These can be applied to assess therapies
given to reverse the dermal sclerosis of chronic GVHD.
 Reduced salivary ﬂow and altered quantitative prote-
omics correlate with histological damage in minor
salivary glands.
 Pathological studies of lung biopsies in patients
meeting the 2005 NIH criteria for bronchiolitis oblit-
erans syndrome (BOS) include both small airway le-
sions of lymphocytic bronchiolitis and constrictive
obliterative bronchiolitis. Open lung biopsy can be
considered in patients with typical pulmonary function
tests and computed tomography (CT) ﬁndings of BOS,
when evidence of chronic GVHD is not present at other
sites.
 Membranous nephropathy andminimal change disease
(MCD) after HCT are associated with chronic GVHD and
appear to be a manifestation of GVHD. Renal biopsy is
recommended for correct classiﬁcation of renal injury
that develops after transplantation.RATIONALE FOR OBTAINING BIOPSIES
The incidence of chronic GVHD varies widely (35% to 70%)
among studies of allogeneic recipients, based upon the time
period speciﬁed, source of hematopoietic stem cells, type of
donor, and post-transplantation immunosuppression. The
risk of chronic GVHD is increased when the source of the
hematopoietic stem cells is derived from growth fac-
toremobilized peripheral blood [9]. As detailed in the NIH
Chronic GVHD Diagnosis and Staging Consensus manuscript
[18], biopsies are necessary to conﬁrm the diagnosis of GVHD
in situations where only distinctive clinical features of
chronic GVHD are present, alternative diagnoses are enter-
tained, clinical signs are conﬁned to internal organs, or
clinical assessment is obscured by prior changes. In these
instances, histopathology should be viewed as essential for
establishing diagnosis, especially if there are any atypical
clinical features, confounding infections, or potential drug
toxicity. Failure to obtain biopsies can result in erroneous
treatment. Jacobsohn et al. found that 7% of patients referred
to Johns Hopkins for consultation regarding chronic GVHD
did not have biopsies before starting treatment and had been
incorrectly diagnosed and treated for active chronic GVHD
Table 1
Histological Criteria for GVHD by Organ System
Organ or System Minimal Criteria for Acute/Active GVHD* Speciﬁc Criteria for Chronic GVHDy
Liver Global assessment of dysmorphic or
destroyed small bile ducts  cholestasis,
lobular and portal inﬂammation
Ductopenia, portal ﬁbrosis,
chronic cholestasis reﬂect chronicity but are not
speciﬁc for chronic GVHD
GI Variable apoptotic criteria (1/piece) in crypts Destruction of glands, ulceration or
submucosal ﬁbrosis may reﬂect severe or
long-standing disease but are not speciﬁc for chronic GVHD
Skin, in general Apoptosis in epidermal basal layer or
lower Malphigian layer or infundibulum/outer
root sheath/hair bulge of hair follicle or
acrosyringium/sweat ducts  lichenoid
inﬂammation  vacuolar
change  lymphocytic satellitosis
Skin, lichen
planuselike
Combination of epidermal orthohyperkeratosis, hypergranulosis and
acanthosis resembling lichen planus 
lichenoid inﬂammation and/or vacuolar changes of eccrine units
Skin morpheic
(localized or diffuse)
Thickening and homogenization of collagen bundles throughout
reticular dermis or pandermal sclerosis with overlying
interface changes  thickening and homogenization of subcutaneous septa
Skin, lichen
sclerosuselike
Homogenization  sclerosis of papillary dermal
collagen with overlying interface changes including
melanophages in the papillary dermis and sparse lymphocytic inﬁltrate
Skin, fasciitis Thickening of fascial septa with adjacent
inﬂammation  sclerosis of subcutis
Oral/oropharyngeal
mucosa and
conjunctiva
Lichenoid interface lymphocytes with
inﬁltration of mucosa (exocytosis) and
variable apoptosisz
Minor salivary or
lacrimal gland
Periductal lymphocytic inﬁltrate with inﬁltration and
damaged intralobular ducts, ﬁbroplasia in periductal stroma, mixed
lymphocytic and plasmacytic inﬂammation with destruction of acinar tissuex
Lung CBO: dense eosinophilic scarring beneath the respiratory epithelium,
resulting in luminal narrowing or complete ﬁbrous obliteration.
May be preceded by lymphocytic bronchiolitis without intraluminal ﬁbrosisk
Kidney Membranous nephropathy, minimal change disease
Lesions of Uncertain Pathogenesis
Lung COP
Skeletal Muscle Myositis
* Conditions that result in lesser degrees of change include immunosuppressive treatment, biopsy very soon after onset of signs, suboptimal or small tissue
sample, insufﬁcient serial sectioning, confounding infection, drug reaction, or inﬂammatory conditions.
y After the diagnosis of chronic GVHD has been established or following immunosuppressive treatment, the histological manifestations of active disease may
meet only minimal diagnostic criteria for activity. Different manifestations of cutaneous chronic GVHDmay all be present together in 1 biopsy or in separate but
concurrent biopsies.
z Inﬂammation of the oral mucosa and within the minor salivary glands may persist from prior chemo-irradiation or prior inﬂammation. The distinction
between acute and chronic GVHD requires the addition of distinctive oral manifestations [18].
x The distinction of past acinar destruction and ﬁbrosis from ongoing chronic GVHD activity can be difﬁcult and relies on assessing lobules that are not
completely ﬁbrotic. Acinar and periductal inﬂammation with features of damage to ducts, such as vacuolar change, lymphocytic exocytosis nuclear dropout,
dyspolarity or apoptosis, and resultant ﬁbroplasia indicate chronic GVHD activity.
k Constrictive bronchiolitis obliterans (CBO) [120] should be distinguished from cryptogenic organizing pneumonia [129], which is also associated with GVHD
but has a different clinicopathologic presentation and a more favorable outcome.
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fungal infection, drug reactions, and Grover’s disease can
mimic chronic GVHD in the skin [20,21].
Although a biopsy can be of value in conﬁrming the initial
diagnosis of chronic GVHD and in demonstrating features of
progression, assessing histological signs of activity may be
difﬁcult. The role of serial biopsies to assess the response to
treatment has not been determined. In addition, the utility of
screening biopsies in asymptomatic patients who are still
taking immunosuppressive medications is controversial, as
asymptomatic patients with positive screening biopsies are
not considered to have chronic GVHD. In the context of
clinical studies, a screening biopsy may serve as a useful
baseline reference point.
LIMITATIONS OF DIAGNOSING GVHD BY
HISTOPATHOLOGY
Diagnostic interpretation by the pathologist requires
integration of the clinical context with the microscopic
changes. Histopathology represents a “snapshot in time” of acomplex and dynamic biologic process that reﬂects the
duration, use of immunosuppressive therapy, the possibility
of more than one process, the location and the quality of the
sample, and the histological preparation. Given the high
prevalence of chronic GVHD in the population of interest, the
positive predictive value of a positive biopsy for GVHD is
high, whereas the negative predictive value is low [22]. As
criteria for the minimal diagnostic threshold become more
stringent, the sensitivity of the biopsy to detect GVHD will
decrease.
A number of factors can cause a false-negative histologi-
cal assessment of GVHD. Biopsies done immediately after the
onset of symptoms and signs of presumptive GVHD may be
falsely negative because results may show only subtle and
focal morphological changes. Tissue sampling may be sub-
optimal. Biopsy of an oral or GI ulcer rather than the adjacent
intact mucosa may not show the changes of GVHD. Thin
needle biopsies of liver and poorly oriented gut biopsies can
distort the relevant structures. Partial thickness biopsies
cannot be used to assess fasciitis or ﬁbrotic changes in the
Table 2
Recommendation for Final Diagnosis Categories
Category Deﬁnition Examples Comments
Not GVHD No evidence for GVHD
Possible
GVHD
Evidence of GVHD but other
possible explanations
 Obvious CMV enteritis with inclusions
near the apoptotic changes
 Focal colonic ulcers with marked apoptotic
cryptitis and destruction of crypts
associated with use of MMF
 Coinfection with known active viral hepatitis
 Clinical features which suggest or
favor a drug reaction
Indicate possible alternate diagnoses
and reasons for suspicion
Likely
GVHD
Clear evidence of GVHD
without a competing
cause of injury
OR
Clear evidence of GVHD
with mitigating factors
OR
GVHD most likely diagnosis
but relevant clinical
information is limited
OR
GVHD is validated by
sequential biopsy or by absence
of competing diagnosis
 Abundant epithelial apoptosis without clinical or
histological evidence of drug injury or infection
 Evidence of CMV yet abundant apoptotic
epithelial changes that are not associated with
CMV infected cells by immunostaining
 Single or rare apoptotic epithelial changes
without other features of active GVHD
and no alternative explanations
 Limited sample or minimal or
focal ﬁndings
 Proximity to recent chemotherapy
or radiotherapy
Included old categories of “consistent with”
and “unequivocal” GVHD
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include enough individual glands (at least 10) that contain
sufﬁcient ducts or glandular acini to differentiate between
active disease and previously damaged glandular tissue, as
not all minor glands in a specimen may exhibit evidence of
active disease. Suboptimally processed and sectioned bi-
opsies may obscure key cytological features. Biopsies that are
too small and glass slides containing only limited numbers of
serial sectionsmay be insufﬁcient for detecting focal minimal
changes. GVHD may be of mild intensity or may be partially
suppressed by immunosuppression. In such cases, it is
difﬁcult to demonstrate that precise minimal diagnostic
criteria are uniformly applied. A false-positive diagnosis of
GVHDmay result from concurrent infections, drug reactions,
or inﬂammatory reactions unrelated to GVHD.
HISTOLOGICAL CRITERIA FOR THE DIAGNOSIS OF GVHD
Although the focus of this series is to provide consensus
on the topic of chronic GVHD, differentiating acute from
chronic GVHD on biopsy material is not always possible.
Features of acute GVHD may present even in organs that
have deﬁned criteria for chronic GVHD. In other sites, sepa-
rable forms of acute and chronic GVHD have not been
deﬁned histologically. Therefore, the following discussion
will treat the histological appearance of GVHD broadly and in
the context of histological and clinical differential diagnosis.
Table 1 presents the criteria necessary to diagnose GVHD
(whether acute or chronic) and the features diagnostic for
chronic GVHD in each involved organ system. The exact
threshold at which a diagnosis of GVHD may be made with
conﬁdence remains a topic for study.
The sections below summarize consensus opinions of
organ-speciﬁc pathology.
Liver
As both drug-induced liver damage and opportunistic in-
fections occur frequently after HCT, the diagnosis of liver
GVHD can be highly challenging. The histological diagnosis of
liver GVHD is based on the identiﬁcation of immune-
mediated destructive damage to small bile ducts andductules, together with cholestatic and inﬂammatory
changes, after considering potential confounding causes of
liver injury. Thebile ducts arewithered, showreactive nuclear
and cytoplasmic changes, and may be inﬁltrated by lympho-
cytes. Unlike GVHD-associated injury of other epithelia,
biliary epithelial apoptoses are infrequent. Hepatocellular
apoptosis (acidophilic bodies) are more frequently observed
in cases of hepatic GVHD than chronic viral hepatitis in pa-
tients without HCT [23]. Theminimum amount of duct injury
required toestablish adiagnosis of hepaticGVHDhasnotbeen
established. If the liver biopsy is done soon after the onset of
liver dysfunction, characteristic bile duct changes may be
absent or may affect only a minority of portal spaces [23].
Inadequate sampling may also cause a false negative result
[23]. The injury reﬂects not only the durationof hepatic GVHD
but also the effects of therapeutic intervention, which may
precede biopsy. Refractory GVHD in the liver is typically
associated with chronic cholestasis, ductopenia, and, less
commonly, a ductular reaction response [6,24,25], unlike
other chronic cholestatic liver diseases. In such cases, it re-
mains unclear whether a prominent ductular reaction rep-
resents a reparativeeffort, a secondary targetofGVHD,orboth
[26]. A ductular reaction may be present with concomitant
gut GVHD or septicemia [27], referred to as cholangitis lenta,
related to the effects of interferon gamma [28].
In the liver, no clear dichotomy exists between acute and
chronic GVHD. However, prolonged persistence of GVHD
may result in progressive ﬁbrosis [23]. Although rare cases of
cirrhosis have been attributed to chronic GVHD [6,24,29],
these reports are confounded by coexisting chronic hepatitis
C infection. Fibrosis present at the onset of acute GVHD or
within the early post-transplantation period is more likely to
reﬂect pretransplantation pathology than chronic injury
from GVHD. In children with chronic liver disorders, the
developing hepatobiliary tract is especially vulnerable to
injury and prone to ﬁbrosis [30].
The Lerner grading scheme for hepatic GVHD is based on
the fraction of bile ducts showing injury [31]. Unlike as for
the original corresponding Lerner grades in the skin and gut,
inﬂammation is not used to establish the diagnosis of GVHD.
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nostic or predictive power, histological scoring of liver GVHD
is currently not recommended.
Special histochemical stains and immunohistochemistry
may be useful in evaluating cases of hepatic GVHD and should
be employed as needed. Bile duct damage and loss may be
highlighted by immunohistochemical (IHC) staining of kera-
tin7or19. Immunohistochemistryor in situhybridization can
help identify viral infection due to cytomegalovirus (CMV),
herpes simplex virus, Epstein Barr virus, varicella zoster virus,
human herpesvirus-6 [32], and adenovirus. Routine staining
for viruses in the absence of suggestive histology is not rec-
ommended, although staining may be performed if clinical
suspicion of infection is high. Iron stains are useful to reveal
hepatic iron overload that contributes to liver dysfunction in
HCT patients, are associated with an increased rate of in-
fections, andmaypredispose thepatient toGVHD [33,34]. The
cellular distribution and severity of iron overload should be
mentioned in the pathology report. Two unusual manifesta-
tions associated with GVHD involve hepatocyte inclusions
recognizedbyperiodic acid Schiff staining. These includeboth
diastase-sensitive polyglucosan-like ground-glass cyto-
plasmic inclusions [35-37] and periodic acid Schiffepositive
diastase-resistant pseudo-Lafora bodies [38]. Data are insuf-
ﬁcient to determine whether IHC staining for replicative
senescence by p21 [39], determination of the Th17/T regula-
tory cell ratio [40], or staining for C4d provides additional
information above and beyond the usual histological
evaluation [41].
When evaluating a potential case of hepatic GVHD,
knowledge of the clinical management (changes in immu-
nosuppressive drugs) and serological and molecular testing
for infectious agents are important for adequate biopsy
interpretation. Patients presenting with an acute hepatitic
onset after donor lymphocyte infusions or tapering of
immunosuppressive medications may have more necroin-
ﬂammatory activity and portal inﬂammation than typically
seen in patients who are receiving immunosuppression
[25,42]. However, in the setting of rapidly rising amino-
transferases in the thousands, one should screen carefully for
viral inclusions and exclude infection through special studies
as noted above. Infection with hepatitis B virus or hepatitis C
virus (HCV) may complicate biopsy interpretation. Chronic
hepatitis C infection causes inﬂammation and reactive bile
duct changes [6,23,43], but the degenerative bile duct
changes of GVHD are qualitatively different from those
caused by HCV. In chronic hepatitis C, the bile duct injury is
usually focal and is usually associated with a lymphoid
aggregate. In contrast, the duct injury in GVHD is usually
present in multiple portal spaces, and the injury is usually
not accompanied by signiﬁcant inﬂammation. A potentially
fatal complication, ﬁbrosing cholestatic hepatitis from hep-
atitis B virus or HCV, may develop in immunocompromised
patients [44,45].
Some studies have shown that serial liver biopsies pro-
vide a clearer picture of the liver disease and lead to better
patient management [23,25,34,46,47]. Early biopsies done
for the acute hepatitic onset of GVHDmay have striking focal
hepatocellular necrosis with minimal bile duct damage [25].
This presentation presumably reﬂects cytokine-induced
bystander death of hepatocytes mediated by the Fas/Fas
ligand interaction of activated T cells with hepatocytes in the
sinusoids. In such cases, subsequent liver biopsies may have
obvious bile duct damage. Serial liver biopsies done to
evaluate persistent liver dysfunction during prolongedimmunosuppression may show a further damage or loss of
bile ducts, along with chronic cholestatic changes. In
contrast, a single liver biopsy obtained after persistent liver
dysfunction can characterize the degree of biliary damage or
destruction but cannot indicate whether the process is pro-
gressive, static, or recovering. Serial liver biopsies may show
that progressive deterioration of presumed GVHD is actually
related to a second process or may help identify features
predicting steroid-refractory disease. Lastly, assessment of
response to therapy requires integration of the clinical and
pathological data, especially with liver biopsies, where
improvement in liver tests may precede improvement in
histology by months. The extent to which improvement in
clinical features correlates with repair and regeneration of
bile ducts is not known. In an anecdotal case with complete
ductopenia, liver tests returned to normal after 1 year [25].
The consensus panel encourages the integration of protocol
liver biopsies when devising future biomarker studies to
identify histological features that may be included in a
multifactorial model to guide clinical management.
The literature on liver GVHD presents conﬂicting data
regarding the relationship of the degree of biliary damage
and outcome. The ominous signiﬁcance of hyper-
bilirubinemia with poor survival has been independently
validated in several studies [46,48-51]. Therefore, it seems
likely that individual histological features should be associ-
ated with the outcome of HCT patients or predict response to
therapy. Yet, because of small sample sizes, case accrual over
long time periods, and changes in conditioning and treat-
ment modalities, comparisons between these histological
studies are difﬁcult [52]. For example, in one study, the
extent of bile duct damage, lymphocytic inﬁltration of biliary
epithelium, portal inﬂammation, and ductopenia showed no
association with survival, whereas severe acinar inﬂamma-
tion and low level of hepatocellular ballooning were associ-
ated with a better outcome [53]. In another study on the
acute hepatitic onset of liver GVHD, extensive destructive
biliary changes, regardless of the degree of inﬂammation,
were associated with an increased risk of nonrelapse mor-
tality [25]. In the collective experience of the group, the
extent of bile duct damage and portal and acinar inﬂam-
mation correlate with the degree of liver test abnormalities
but not necessarily with the outcome of liver GVHD. How-
ever, the degree of bile duct loss seems to be associated with
decreased survival. Thus, liver biopsies may serve not only as
a diagnostic tool for establishing the diagnosis of liver GVHD,
but when integrated with the clinical context, may provide
additional prognostic information that could help identify
patients at high-risk for fatal outcome.
GI Tract
The histopathology in the GI tract is variable during late
onset acute, persistent, or chronic GVHD. Endoscopic or
imaging evidence of esophageal webs remains the only
uniformly accepted diagnostic feature of chronic GVHD
within the GI tract [18], and histological changes are not
helpful in distinguishing chronic GVHD from acute GVHD.
Prolonged or incompletely treated forms of acute GVHDmay
leave behind extensive architectural distortion [54]. Changes
of chronicity include marked architectural distortion of
mucosal architecture with crypt loss; formation of cystic
glands or disorganized crypts not connected with the sur-
face; areas of atrophy alternatingwith partial regeneration or
ulcerations, often with nuclear hyperchromasia; little asso-
ciated inﬂammation or apoptosis; and loss of cytoplasmic
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plasmacytic inﬂammation, colonic Paneth cell metaplasia,
lamina propria ﬁbrosis, and rarely, submucosal or serosal
ﬁbrosis [1,3,7,54].
The histological hallmarks of gastrointestinal GVHD are
some combination of enterocyte apoptosis, crypt or basilar
gland destruction, and mucosal denudation. The term crypt
apoptosis is used here to refer to gastric pit apoptosis as well
as crypt apoptosis in the intestines. The changes of gut GVHD
are most prevalent and easiest to identify in biopsies from
the large and small intestine. Apoptotic debris limited to the
superﬁcial epithelium and lamina propria is a nonspeciﬁc
ﬁnding and should not be used to diagnose GVHD unless the
tissue shows only surface mucosa with complete destruction
of underlying crypts, as may occur with prolonged gut GVHD.
However, the recognition of apoptosis is not always simple,
and an ongoing study by a European pathology consortium
suggests that interpretive variation can be addressed
through consensus on study sets. Apoptotic bodies may
appear as exploding crypts [55], as hyperchromatic karyor-
rhectic nuclear debris within a large clear zone, or as a small
shrunken cell with eosinophilic cytoplasm and a condensed
nucleus.
Numerous changes in transplantation practices and the
effects of prolonged immunosuppression have altered the
severity and onset of GVHD, leading to increased willingness
to diagnose GVHD based on minimal histological changes
(speciﬁcally apoptosis) in the appropriate setting. Yet,
deﬁning the exact threshold of minimal histological change
sufﬁcient for the diagnosis of GVHD remains controversial.
Attempts to set a threshold of apoptosis involve a tradeoff
between sensitivity and speciﬁcity. Using a threshold similar
to that used for acute cellular allograft rejection in small
bowel transplantations (6 of 10 consecutive crypts) [56,57]
was felt by the consensus group to be too insensitive. Others
have demonstrated that using the previously recommended
> 1 to 2 apoptotic bodies per biopsy piece (on average) in-
creases sensitivity with some loss of speciﬁcity [58,59]. The
injury in GI GVHD is unevenly distributed, which increases
the difﬁculty of establishing a threshold of histological
change for the diagnosis of GVHD. A false negative diagnosis
may result from a limited biopsy sampling or examination of
too few serial sections. At least 8 and up to 20 serial sections
should be analyzed to avoid missing infrequent apoptotic
changes. The use of IHC markers of apoptosis (eg, caspase 3)
has been limited to research studies and has not yet found
utility in routine clinical practice.
Enterocyte apoptosis is not limited to GVHD. Infections
associated with apoptosis (CMV, cryptosporidia) were dis-
cussed in the earlier document [10]. Special studies may be
performed to highlight infection, as noted in the hepatic
GVHD section above. Drug-induced GI injury may induce
enterocyte apoptosis and mimic GVHD. Since the last
consensus document, numerous publications have described
GI toxicity associated with MMF. In the upper GI tract, one
may see parietal cell ballooning, chronic active gastritis,
active esophagitis, and celiac-like features in the duodenum
[59-64]. The presence of focal colonic ulceration, marked
apoptosis, mixed inﬂammation, and interspersed normal
mucosal biopsies from sites distant to the lesions should
raise the possibility of MMF-related colitis [61]. Contrary to
early reports [65], the presence of an increased number of
eosinophils within the lamina propria and epithelium should
favor a diagnosis of MMF-induced injury over GVHD [66,67].
Additionally, loss of neuroendocrine cell nests was seen inMMF-related injury as opposed to GVHD, which spares
neuroendocrine cells [67,68]. The frequency of MMF toxicity
is difﬁcult to quantify in this patient population because of
the overlap in pathology between GVHD andMMF toxicity. In
clinical practice, MMF toxicity is favored if discontinuation or
dose reduction improves symptoms. With respect to other GI
drug injury, mild gastric antral apoptosis has been reported
with the use of proton pump inhibitors and nonsteroidal
anti-inﬂammatory drugs [69].
In the previous NIH histopathological diagnosis of chronic
GVHD consensus document [10], the standard use of histo-
logical grading was not recommended because the existing
grading schemes (Lerner [31] and the Sale modiﬁcation [1])
combine diagnostic criteria with the extent and chronologic
stage of disease. Although severe changes (Lerner grade 4)
are associated with poor survival [70], the degree of injury
required for grade 1 is poorly deﬁned and includes a broad
spectrum of apoptotic activity from rare to numerous, falling
just short of exploding crypts. The committee was divided as
to the utility of using these grading systems in routine
practice. If an institution chooses to use a grading system, the
site with the greatest damage or highest histological grade
should be noted because of the inherent variability in injury.
Additional morphologic features that correlate with disease
severity or nonrelapse mortality include the loss of Paneth
cells within the small intestines and crypt loss within the
colon [12,71]. Given the drawbacks of the existing histolog-
ical grading systems, we would recommend investigating
grading schemes based on the degree of apoptotic activity
independent of the stage of crypt or mucosal destruction.
Cord colitis syndrome was described as a newly entity in
2011 by Herrera et al. at the Dana Farber Cancer Institute
[72]. This syndrome, conﬁned to their cord blood recipients,
was characterized by late-onset secretory diarrhea, chronic
active colitis and multicentric granulomas, absence of GVHD
or detectable infections, responsiveness to antibiotics, and
lack of responsiveness to immunosuppressive treatment. The
Dana Farber Cancer Institute investigators used a nonstan-
dard deﬁnition of GVHD that did not characterize as GVHD
colonic biopsies that showed any features of chronicity as
described above, and instead, included them as cord colitis
syndrome. Subsequently, 2 much larger studies including
controls who received cord blood and nonecord blood he-
matopoietic stem cell transplants showed that neither the
histological features of chronicity (crypt distortion, Paneth
cell metaplasia, chronic active colitis) nor granulomas were
conﬁned to cord blood recipients [73,74]. In the study by
Milano et al., all of the nonecord blood allogeneic recipients
with late onset secretory diarrhea and symptoms ascribed to
cord colitis syndrome responded to anti-GVHD treatment
[73]. The presence of granulomas with neutrophilia was
more common in a Japanese study that included many cases
with both GVHD and CMV [74]. These studies serve as a
reminder that GVHD and infection are notmutually exclusive
diagnoses and reinforce the need to use standardized his-
tological deﬁnitions for GVHD.
As noted before [10], the gold standard in diagnosing GI
GVHD remains unsettled among transplantation clinicians,
pathologists, and endoscopists. Several groups require only
evidence of GVHD involvement in other organs [54,75,76]
whereas others use response to immunosuppressive ther-
apy alone as an indication of GVHD [15,77]. Involvement of 1
organ system by GVHD, however, does not necessarily imply
coexisting GI GVHD. As noted above, infectious etiologies and
drug injury may mimic GVHD. Some have proposed that the
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GVHD, as the extent of mucosal changes can be visualized
more completely [78]. Discrepancies between upper or lower
endoscopic ﬁndings, however, are well documented, as are
differences between clinical, endoscopic, and histological
diagnoses [71,75,79-84]. Consensus that sampling one
particular site of the GI tract is consistently better than
another is lacking. The highest diagnostic yield occurs when
visibly injured or erythematous regions of both the upper
and lower gut are sampled [83]. On a practical level, the
diagnosis of GI GVHD still requires an assessment of clinical,
endoscopic, and histological ﬁndings and exclusion of other
causes of injury.
Several studies have compared the ability of clinical,
endoscopic, and histological ﬁndings to predict response to
steroid treatment and risk of death [71,78,79,81]. It is difﬁcult
to reconcile the differing conclusions regarding the best
predictor, as some studies were based only on evaluation of
the colon [71,78,81], whereas another study was conﬁned to
the upper GI tract with a focus on biopsies from the second
portion of the duodenum [79]. There was general agreement
thatmost endoscopic biopsies taken shortly after the onset of
gut symptoms of GVHD were typically of lower histological
grade; however, those with higher-grade injury have been
correlated with poor outcome. Intestinal biopsies taken after
immunosuppressive treatment and showing persistent or
worsening histological changes portended a poor outcome,
in agreement with endoscopic and biomarker observations
[12,70,79]. A relevant immunohistologic study showed that
the numbers of regulatory T cells in blood and gastric
mucosal biopsies did not correlate with clinical or histolog-
ical severity of GVHD [85].
Skin
Two comprehensive, richly illustrated reviews have
described the gross and microscopic manifestations of
cutaneous chronic GVHD [8,86]. A consensus document
speciﬁc to cutaneous GVHD biopsy performance and
reporting is also available [87]. The minimal histological
criteria for GVHD require apoptosis within the basilar or
lower spinosum layers of the epidermis [1,5,31]. In cases of
minor alteration, the focus should be on the interpretation of
vacuolar changes and apoptotic keratinocytes, including in
the adnexal epithelia, although in the case of lichenoid dis-
ease, some element of inﬂammation should be present to
allow the diagnosis to be established with conﬁdence [88].
The archetypical features of both acute and chronic GVHD are
superﬁcial interface dermatitis with vacuolar change pre-
dominantly in the basilar layer or a lichenoid pattern of
lymphocytic inﬂammation with or without lymphocyte sat-
ellitosis [4,5,89]. As a note of caution, because no single
histological feature is pathognomonic of GVHD, the pattern
of inﬂammation should be factored into the ﬁnal interpre-
tation [90]. For example, exuberant superﬁcial spongiotic
dermatitis with marked spongiosis (intraepidermal edema)
and lymphocytic inﬁltration into the epidermis with only a
rare apoptotic keratinocyte may suggest an allergic contact
dermatitis but encompasses a broad differential and likely
excludes the diagnosis of GVHD. The presence of tissue
eosinophils in a skin biopsy should not be considered as
evidence for drug hypersensitivity, as they often occur in
GVHD [91]. Lymphocyte satellitosis (lymphocytes abutting
an apoptotic keratinocyte in the epidermis or appendages),
when present, provides evidence that the dermatitis may be
caused by GVHD. This characteristic feature is not entirelyspeciﬁc and can occur in drug reactions. Of note, Nishiwaki
et al. noted that many cells in the dermal inﬂammatory
inﬁltrate in untreated acute GVHD were actually CD163þ
macrophages rather than T cells. Dermal macrophages pre-
sent in large numbers correlated with steroid refractoriness
and lower survival [11].
The histological manifestations of chronic cutaneous
GVHD evolve over time, are modiﬁed by treatment, and to
some extent overlap with those of acute GVHD. Severe ker-
atinocyte dysmaturation related to conditioning with
busulfan can persist for many months after HCT [92]. The
histological counterparts to the clinical deﬁnitions of cuta-
neous chronic GVHD include several different histological
patterns. The lichen-planuselike eruptions (initially classi-
ﬁed as early generalized extensive chronic GVHD [2,4] refer
to a speciﬁc constellation with epidermal thickening by
acanthosis (hyperplasia) with orthohyperkeratosis (stratum
corneum) and parakeratosis, hypergranulosis, a band-like
inﬁltrate along the dermal-epidermal junction, extensive
apoptosis, and vacuolization of basilar keratinocytes, saw-
toothed (tapered and elongated) rete ridges, plus inﬂam-
mation around the adnexae. This constellation, especially
when accompanied by lymphoplasmacytic inﬂammation
around the eccrine coils, is highly speciﬁc for chronic GVHD
but has low sensitivity. In a patient with chronic skin GVHD,
biopsy may show both acute and chronic GVHD, and the
changes of chronic GVHD may vary from one site to another.
In practice, members of the dermatopathology subcommit-
tee regarded a skin biopsy with the combination of
epidermal compact orthohyperkeratosis, hypergranulosis,
and acanthosis with shortened or saw-toothed rete ridges as
features that favor or are consistent with lichenoid type of
chronic GVHD. Rarely, milder forms of this combination of
features can occur in skin biopsies from patients with severe
clinical acute GVHD. Screening biopsies from nonesun-
exposed normal appearing skin, such as iliac crest, taken
between day 80 and 100 after transplantation often contain
rare isolated keratinocyte apoptotic bodies with little or no
accompanying inﬂammation [93]. The interpretation of such
ﬁndings as either nonspeciﬁc or consistent with minimal
(subclinical) GVHD depends on an institution’s minimal
diagnostic criteria.
In the initial descriptions of sclerotic or late chronic
GVHD, the ﬁbrosis that followed the lichenoid stage had a
top-down progression from the papillary through reticular
dermis [2,5]. Some patients develop diffuse dermal sclerosis
without an apparent inﬂammatory lichenoid phase. The
suggested minimal criterion for the diagnosis of cutaneous
sclerotic chronic GVHD is homogenization (sclerosis) of most
of the papillary dermis or reticular dermis or subcutaneous
septa. Depending on the clinical presentation, sclerotic
GVHD can manifest with localized morphea-like features,
diffuse sclerosis or lichen sclerosus-like features. Localized
morphea-like features and diffuse sclerosis are largely
conﬁned to the reticular dermis or subcutaneous septa with
little or no epidermal involvement. In lichen sclerosus-like
GVHD, collagen alteration is conﬁned to the papillary
dermis, often with residual interface changes characterized
by the presence of mild vacuolar alteration, melanophages,
and sparse lymphocytic inﬁltrate in the papillary dermis.
Localized lesions in areas of minor trauma such as needle
sticks may represent Koebnerizing GVHD [94]. In the fasciitis
variant, biopsy specimens show only ﬁbrous thickening of
the fascia with adjacent inﬂammation without epidermal or
dermal involvement [95]. Recent work has characterized
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[86,96]. Table 1 lists several different manifestations of
chronic GVHD, all of which may be present in a single biopsy.
After immunosuppressive treatment, a skin biopsy may
contain a combination of residual changes to the damaged
epidermis and appendages, any pre-existent dermal scle-
rosis, and a reduction or absence of apoptosis and inﬂam-
mation. An indication of active GVHD is residual apoptotic
changes in the epidermis or appendages. During treatment,
the histological signiﬁcance of persistent epidermal vacuolar
degeneration requires additional correlative study, as does
the assessment of activity in patients who have received
psoralen and ultraviolet A irradiation or who have estab-
lished deep dermal sclerosis or morpheic chronic GVHD. Of
note, additional, long-term use of steroids may also induce
epidermal atrophy with loss of rete ridges. Both clinical and
histological regression of dermal sclerosis occurs a year or 2
after psoralen and ultraviolet A irradiation therapy for
chronic GVHD and autologous transplantation for sclero-
derma [97]. Nash et al. have developed a schema for grading
the reduction in dermal sclerosis [98]. These tools can be
used in future studies that seek to produce regression of
dermal sclerosis. A similar, though more complicated,
scheme for grading the regression of sclerosis was designed
by Verrecchia et al. [99].
The pathogenesis of the dermal sclerosis and its rela-
tionship to the dermal microvasculature was studied by
Biedermann et al. [13]. They reported a correlation of dermal
sclerosis in chronic GVHD with elevated concentrations of
von Willebrand Factor (vWF) in the blood and reduced
capillary density identiﬁed by Ulex europeus lectin staining.
Biedermann concluded that reduced vascularity was
responsible for the ﬁbrosis and they further postulated that
the presence of perivascular T cells suggested that the
endothelium was the target. However, vWF multimers are a
nonspeciﬁc acute phase reactant, and the antigen recognized
by lectin staining may be reduced in the presence of
inﬂammation. In contrast, Fleming et al. used the speciﬁc
endothelial markers CD31 and VE-cadherin and did not ﬁnd
a correlation between the dermal ﬁbrosis in chronic GVHD
and a reduction in dermal capillary density [100]. They
further showed that the endothelial microvasculature in
chronic GVHD did not have the reduced VE cadherin and
vWF expression observed in capillaries from patients with
systemic sclerosis. Two related studies using capillaroscopy
on nailfold capillaries conﬁrmed the ﬁndings of Fleming et al.
that patients with scleroderma, but not with chronic GVHD,
had both morphologically abnormal capillaries and reduced
density [101,102].
Mucosa: Oral Cavity, Oropharynx, Eye, and Female
Genitalia
Patients without any signs or biopsy evidence of GVHD
may have chronic inﬂammation without apoptotic changes
in the oral mucosa and minor salivary glands, as demon-
strated by studies of oral labial biopsies taken at 80 to
100 days after HCT. These changes were attributed to
chemotherapy or irradiation in the conditioning regimen
[103]. Theminimal histological criteria for oral chronic GVHD
have remained unchanged. Mucosal changes consist of
localized or generalized epithelial changes (lichenoid inter-
face inﬂammation, exocytosis, and apoptosis) similar to
those described in cutaneous GVHD. Minor salivary glands
show intralobular or periductal lymphocytic inﬂammation
and exocytosis of lymphocytes (without neutrophils) intointralobular ducts (the small intercalated ducts or larger
striated ducts) and acini. Periductal ﬁbrosis without gener-
alized interstitial ﬁbrosis is often present. Nakhleh et al. used
a threshold of > 3 mucosal apoptotic bodies, and for salivary
changes, > 10% loss of acinar tissue or ductal epithelial cell
necrosis as their minimal criteria for GVHD [104]. Horn et al.
developed a histological grading system for chronic GVHD of
minor salivary glands based on the degree of lymphocytic
inﬁltration and destruction of glandular acini [105]. Soares
et al. found that the most speciﬁc histological feature of oral
chronic GVHD was minor salivary gland periductal lympho-
cytic inﬂammation with exocytosis, which correlated with
extensive chronic GVHD and decreased survival [106].
Although the reduction in glandular acinar area was greatest
in patients with chronic GVHD, some reductions also
occurred in those without GVHD. Moderate to intense peri-
ductal and periacinar ﬁbroblastic stroma is evidence of pre-
vious inﬂammation or chronic GVHD activity, whereas dense
ﬁbrous tissue with destruction of acinar tissue and duct
ectasia may be only a marker for previous non-GVHD dam-
age, such as chronic obstructive sialadenitis secondary to
trauma [107].
Persistent salivary dysfunction after treatment of chronic
GVHD is related to progressive lymphocytic inﬂammation
with absence of recovery or destruction of minor salivary
secretory units [107]. Oral chronic GVHD is highly correlated
with xerostomia, reduced salivary ﬂow rates, and xeroph-
thalmia. In a recent study, all patients with salivary
dysfunction had histological damage to the minor salivary
glands with mononuclear inﬁltration, ﬁbrosis, or atrophy
[108]. Involvement of the oral mucosa did not correlate with
salivary dysfunction [108]. In the future, quantitative prote-
omic analysis of saliva may be added as a biomarker to
identify active oral chronic GVHD, especially in newly diag-
nosed patients within the ﬁrst 12 months after HCT [109].
Quantitative proteomic analysis of saliva from patients with
and without oral chronic GVHD demonstrated altered
expression in the chronic GVHD group with decreased IL-1
antagonist receptor and cystatin B compared with the non-
GVHD group. Glandular atrophy, ﬁbrosis, and inﬂammatory
inﬁltrate were all associated with salivary gland dysfunction
in a cohort of patients with oral chronic GVHD [108].
The diagnosis and staging document [110] and other re-
views [8] provide a detailed description of the oral changes of
chronic GVHD. Nonetheless, clinicians and pathologists
should be aware that premalignant dysplasias and oral can-
cers, a leading cause of secondary malignancies after allo-
geneic transplantation, must be considered in the evaluation
[111,112].
The same criteria described above for oral and esophageal
mucosa are used for histological assessment of chronic GVHD
in vulvar [113], conjunctival, and lacrimal biopsies. Histo-
pathological ﬁndings of ocular GVHD have been described in
conjunctiva and in the lacrimal gland [103,114-117]. The al-
terations in lacrimal gland acinar tissue resemble those in
minor salivary glands with prominent inﬁltration of mono-
nuclear cells around medium-size ducts and loss of acinar
lobules replaced by ﬁbrosis. Although lacrimal gland biopsy
is relatively invasive and may impair function, conjunctival
biopsy may be obtained with little risk. Histological evalua-
tion of conjunctiva may aid in the diagnosis and manage-
ment of ocular GVHD in symptomatic patients with
conjunctival disease who have normal or unchanged
Schirmer’s test with or without GVHD of other organs
[115,118,119], and in cases where the diagnosis of ocular
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tested with the use of special stains for viral involvement
when indicated. Conjunctival histological features of GVHD
include lymphocyte exocytosis, satellitosis, vacuolization of
the basal epithelium, and epithelial cell necrosis, similar to
changes that are observed in other organs [114-118]. Other
features are relatively nonspeciﬁc, including epithelial
attenuation and goblet cell depletion, and are not sufﬁcient
for the diagnosis of ocular GVHD [117]. Corneal and
conjunctival pseudomembranous histological ﬁndings are
clinical manifestations generally associatedwith acute ocular
GVHD [118-120].
Lungs
The pathologic ﬁnding of constrictive bronchiolitis oblit-
erans (CBO) is considered as a diagnostic feature of pulmo-
nary chronic GVHD. CBO resembles chronic lung allograft
rejection [121], systemic pulmonary Castleman’s disease
[122], postinfectious scarring, and toxic fume exposure
[123,124]. The bronchioles show intraluminal connective
tissue and chronic inﬂammation that develop into dense
ﬁbrotic scarring of the bronchioles, resulting in luminal
narrowing. Secondary changes include distal mucostasis or
aggregates of foamy macrophages. Bronchiectasis may
develop late. The extent and severity of changes should be
correlated with functional studies, particularly if only a sin-
gle affected airway is present in the biopsy. Other causes,
such as infection and chronic aspiration, should be excluded
[121].
The 2014 NIH chronic GVHD diagnosis and staging
document states that open lung biopsy may be considered if
the characteristic pulmonary function tests and CT ﬁndings
of BOS are not accompanied by a distinctive manifestation of
chronic GVHD in another organ system in a patient without
prior diagnosis of chronic GVHD [110]. Two recent studies
point out that the clinical syndrome of BOS [125] encom-
passes several entities. The study by Holbro et al., based on
33 open lung biopsies for suspected histological CBO, re-
ported discrepancies between the histological ﬁndings and
the NIH consensus criteria [126]. One half of the 14 biopsies
with histological CBO did not meet the clinical consensus
criteria for BOS. In addition, of the 9 biopsies with lympho-
cytic bronchiolitis (LB), lymphocytic inﬂammation around
and inﬁltrating small airways without subepithelial ﬁbrosis,
3 met the NIH consensus for BOS. LBmay represent an earlier
stage in the ﬁnal common pathway towards the develop-
ment of histological CBO from several different disorders,
including viral infection as suggested in a recent review
[127]. Although CBO and LB had similar pulmonary function
tests and clinical manifestations, the patients with LB fared
considerably better with treatment and had improved sur-
vival compared with those with CBO. Many of the discrepant
cases with clinical BOS had infection without histological
CBO. A study by Gazourian et al. also found a variety of
pulmonary histopathological changes in the autopsy lungs of
35 patients who lived at least 1 year, 80% of whom had
chronic GVHD (Gazourian et al., abstract presented at the
2014 Annual Meeting of the American Thoracic Society).
Airway disease was present in 33 cases, and clinically
unrecognized interstitial ﬁbrosis and pulmonary veno-
occlusive disease were seen in 8 and 12 patients, respec-
tively. Thus, the clinical term of BOS may more accurately
reﬂect the variety of pulmonary pathologies associated with
pulmonary function test airﬂow disturbances. A recently
described CT methodology, termed parametric responsemapping, quantiﬁes normal parenchyma total lung volume,
functional small airways, emphysema, and parenchymal
disease as relative lung volumes. Parametric response map-
ping was able to identify BOS, even in the presence of con-
current infection [128].
Cryptogenic organizing pneumonia (COP) (formerly
termed idiopathic bronchiolitis obliterans organizing pneu-
monia) is associated with both acute and chronic GVHD. COP
is a pathologic process deﬁned by plugs of granulation tissue
that ﬁll the lumens of the distal airways including the res-
piratory bronchioles in a patchy distribution, extending into
the alveolar ducts and alveolar sacs, and associated with
chronic interstitial inﬂammation [129]. COP should be
distinguished from CBO because COP has a different clini-
copathologic presentation and a more favorable outcome.
Kidney
Acute and chronic kidney diseases occur frequently after
HCT. Acute renal failure occurs in 30% to 50% of patients, and
chronic kidney disease (CKD) occurs in up to 60% to 70% of
patients. An accumulating body of evidence has linked
chronic GVHD with several kidney disorders, including
nephrotic syndrome (NS) with or without renal insufﬁciency
[130], membranous nephropathy [130-132], transplantation-
associated microangiopathy and CKD). More recent studies
measuring urinary cytokines [133] and elaﬁn [134] indicate
that most of the renal conditions associated with GVHD are
secondary to the cytokines within the inﬂammatory milieu
and not due to toxicity from pre-transplantation condition-
ing or toxicity from calcineurin inhibitors. Nonetheless, the
toxicity of cyclosporinmay be potentiated by cytokine effects
from the presence of a chronic inﬂammatory state [135]. For
a more comprehensive review, the reader should refer to
Chang et al. [130].
Nephrotic syndrome may occur with or without renal
insufﬁciency (reviewed in [136]). Patients usually present
with proteinuria, edema, and hypoalbuminemia. Most case
reports demonstrated membranous nephropathy with sub-
epithelial glomerular deposits, and it is postulated that these
deposits represent antigen-antibody complexes. It is un-
known whether these deposits are directed against endog-
enous antigens expressed in the kidney, thus representing a
direct immunologic attack by GVHD against the kidney, or if
they are derived from antigens expressed elsewhere, such
that the kidney injury occurs through indirect bystander
mechanisms. Cases of MCD have also been described [136].
Based on published case reports, membranous nephropathy
occurs in 61% of NS cases and MCD occurs in 22% of NS cases
[137]. Both MCD and membranous nephropathy occur later
after transplantation, at 8 and 14 months, respectively, and
tend to occur within 1 to 5months after the onset of GVHD or
the tapering of immunosuppression during treatment for
chronic GVHD. Others have reported cases of diffuse prolif-
erative glomerulonephritis, antinuclear cytoplasmic
antibody-related glomerulonephritis, focal segmental glo-
merulosclerosis, and IgA nephropathy [138-142] occurring
after HCT. The development of each of these diseases appears
to be associated with chronic GVHD that is unmasked when
immunosuppression is tapered, similar to the development
of acute hepatitic liver GVHD. Chronic kidney failure is also
associated with GVHD, even after infection and toxicity from
pretransplantation conditioning are excluded [131]. In an
autopsy study of renal pathology in 6 autologous and 20
allogeneic HCT patients, renal tubulitis identical to that seen
in renal allograft rejection was present in 67% of patients,
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associated with more severe forms of GVHD [143,144].
Tubulitis may account for some of the renal dysfunction in
patients with chronic GVHD.
Renal biopsies are needed to clarify these ﬁndings and
guide therapy, especially in patients with proteinuria pre-
senting at day 80 to 100 after HCT.Other Sites
Several other sites of chronic GVHD are less commonly
involved or biopsied. Myositis is a phenomenon that is
clearly associated with chronic GVHD. A comprehensive
description with comparison to other myositis entities has
not been made. The changes in skeletal muscle range from
mild perimysial lymphocytic inﬁltrates to extensive endo-
mysial inﬂammation with necrosis and regeneration of ﬁ-
bers. Clinical presentations and pathologic changes
resembling both polymyositis and dermatomyositis have
been reported [145,146].
Biopsies may be useful in the evaluation of other rare
manifestations that may be related to chronic GVHD. These
syndromes include inﬂammatory neuropathies and synovi-
tis. Chronic GVHD has been reported to cause obliterative
coronary artery changes resembling transplantation athero-
sclerosis [147]. Autopsy studies of lymphoid organs of pa-
tients with chronic GVHD have demonstrated profound
lymphoid depletionwith loss of or only rudimentary residual
primary germinal centers [2].STANDARDIZED REPORTING OF GVHD IN THE
PATHOLOGY REPORTS
In the prior document [10], we proposed terminology that
can be used to qualify the certainty of a histological diagnosis
of GVHD from any particular site (Table 2 in ref [10]). This
schema separates the objective histological ﬁndings in the
microscopic description from the subjective global inter-
pretation and allows the diagnosis to be expressed as a
continuum rather than “yes” or “no.” This approach has been
subjected to study for reproducibility by a European con-
sortium [148]. Based on this study, we recommend reducing
the categories for the diagnosis of GVHD from 4 to 3: Not
GVHD, Possible GVHD, and Likely GVHD (Table 2). The cate-
gory of “Likely GVHD” combines the prior categories of
“consistent with” and “unequivocal” into a single category
(synonymous with probable, favor, or suggestive). The
pathologist should add these qualiﬁers, as needed in the ﬁnal
diagnosis. In line with this update, the 2014 NIH Diagnosis
and Staging document considered a biopsy read as “likely
GVHD” sufﬁcient to establish the diagnosis of chronic GVHD
if accompanied by at least one distinctive clinical feature of
chronic GVHD [110].
In addition to the diagnosis of GVHD, the pathology report
should convey at least qualitative information on the severity
of the injury as well as any additional ﬁndings of note. If a
semi-quantitative grading system is used, references to the
particular system should be recorded. A common under-
standing regarding the application of grading systems be-
tween the pathologists and the clinical staff should be
established. No new recommendations regarding data
collection and formal communication from clinicians to pa-
thologists are made. These forms can be found in the previ-
ous document [10].AREAS FOR FURTHER STUDY AND NOTES ON CLINICAL
STUDIES INCORPORATING PATHOLOGY
Diagnostic criteria for minimal degrees of GVHD remain
variably deﬁned, subject to institutional variation. Examples
of minimal criteria to diagnose GVHD for which further study
is needed include the number of apoptotic bodies required in
a skin, oral mucosal, or gastric biopsy; the need for apoptosis
when lymphocytic exocytosis is present in a skin or mucosal
biopsy taken immediately after the onset of symptoms; the
amount and location of inﬂammation in the minor salivary
glands required for the diagnosis; the extent or degree of
interlobular bile duct changes and portal inﬁltration in liver
injury; and whether inﬂammatory peribronchiolar changes
are a precursor to constrictive bronchiolitis obliterans.
This problem of minimal criteria may not have a discrete
solution. When histological changes deviate only slightly
from normal, histological “noise” may be interpreted as a
signal indicating disease. In other areas of pathology, this
problem is addressed by introducing a category of borderline
change that has clearly deﬁned boundaries. The clinical
response to such a diagnosis might be to withhold therapy,
watch closely, and resample if necessary, or proceed with
therapy if the clinical suspicion is high and initial sampling is
limited. Because apoptotic cell injury is a characteristic of
both skin, oral mucosal, and GI GVHD that may be seen at any
stage, the panel discussed developing grading schemes
based on the extent of apoptotic change. Ideally, such a
systemwould be reproducible and simple to apply, would set
thresholds for borderline and deﬁnite GVHD, and thereby
help guide clinical decision-making.
Initial studies could have a retrospective design, with
blinded re-evaluation of biopsies according to predeﬁned
criteria and with adequate follow-up information on any
therapeutic intervention and clinical course. Case selection
should focus on mild disease to deﬁne thresholds for thera-
peutic intervention more clearly. Multi-institutional studies
are needed in an effort to decrease practice variation and
increase the applicability of any ﬁndings. Prospectively
designed studies would allow testing of proposed thresholds
according to standard treatment protocols. Prospective
studies could also serve to collect biosamples in parallel with
biopsies for biomarker discovery. Ideally, standardized
collection of biopsy data should be part of any prospective
study, even if the study is not speciﬁcally designed to address
a diagnostic issue.
Pathologists should be involved in the early stages of any
study design. Observer variability must be minimized,
possibly through on-line image atlases and consensus re-
views. Sampling strategies, particularly with respect to
evaluation of GI GVHD, should be standardized as much as
possible. Although it is difﬁcult to enroll patients in studies
that have histological entry criteria, tissue-based diagnosis
should be encouraged whenever possible, so that protocols
designed to evaluate therapies are based on the most com-
plete diagnostic information and biomarker discovery can be
founded on histological ﬁndings.
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